Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study
- 18 November 2021
- journal article
- research article
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 67 (3) , 226-234
Abstract
Objective: The objective of this study was to analyze the real-world prevalence of long-acting injectable (LAI) antipsychotic use and determine when LAIs are being used in sequencing of antipsychotic medications among Canadian patients with schizophrenia. Methods: This was a retrospective, longitudinal cohort study using Canadian pharmacy prescription data between August 2005 and June 2017. Patients with inferred schizophrenia spectrum disorder were indexed on the date of their first antipsychotic prescription and analyzed for minimum 12 months to track lines of antipsychotic therapy and LAI utilization. Results: A total of 16,300 patients were identified for analysis. 48.2% and 46.0% of index antipsychotic prescriptions were prescribed by a general practitioner/family medicine doctor and psychiatrist, respectively. 1,062 (6.5%) patients used an LAI during the study period. Of those patients, 789 used an LAI within two years of index (74.3% of LAI users; 4.8% of all patients). The majority of LAI use (62.0%) occurred in the third line of therapy or later. 65.0% of patients had tried at least two therapy lines, and most patients reported gaps of six months to one year between treatment lines. Conclusion: Despite their potential to reduce relapse in schizophrenia by improving treatment adherence, this study shows LAIs continue to be under-utilized in Canada. When used, LAIs are positioned late in sequencing of antipsychotic medications, often not initiated until years after diagnosis. Continued preference for oral APs with poor adherence may be negatively impacting prognosis and exacerbating burden of schizophrenia. Efforts should be invested to understand barriers to LAI uptake and advocate for earlier, widespread use of LAIs.Keywords
Funding Information
- Janssen Pharmaceutica
This publication has 41 references indexed in Scilit:
- Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaPatient Preference and Adherence, 2013
- Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophreniaBMC Psychiatry, 2013
- Long-acting Injectable Antipsychotics in First-episode SchizophreniaClinical Psychopharmacology and Neuroscience, 2013
- Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nursesBMC Psychiatry, 2013
- The nature of relapse in schizophreniaBMC Psychiatry, 2013
- The Myth of Schizophrenia as a Progressive Brain DiseaseSchizophrenia Bulletin, 2012
- Burden of informal care giving to patients with psychoses: A descriptive and methodological studyInternational Journal of Social Psychiatry, 2011
- Risperidone Nonadherence and Return of Positive Symptoms in the Early Course of SchizophreniaAmerican Journal of Psychiatry, 2011
- Quality of life in caregivers of patients with schizophrenia: A literature reviewHealth and Quality of Life Outcomes, 2009
- Partial Adherence to Antipsychotic Medication Impacts the Course of Illness in Patients With SchizophreniaThe Primary Care Companion For CNS Disorders, 2009